n.a. (ZLCS)

5.39
0.00 (0.00)
NASDAQ
Prev Close 5.39
Open 5.60
Day Low/High 5.26 / 5.60
52 Wk Low/High 3.78 / 16.90
Volume 177.07K
Exchange NASDAQ
P/E Ratio 0.34
Div & Yield N.A. (N.A)
Zalicus To Present At Noble Financial’s Seventh Annual Equity Conference

Zalicus To Present At Noble Financial’s Seventh Annual Equity Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Justin Renz, Senior Vice...

Zalicus Reports Financial Results For The First Quarter 2011

Zalicus Reports Financial Results For The First Quarter 2011

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the first quarter ended March 31, 2011.

Zalicus To Present At The Tenth Annual JMP Securities Research Conference

Zalicus To Present At The Tenth Annual JMP Securities Research Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

4 Biotech Penny Stocks to Buy: Navellier

4 Biotech Penny Stocks to Buy: Navellier

YM Biosciences is among four hot-performing biotech penny stocks that merit a look from investors.

Zalicus Granted Composition-of-Matter Patent For Synavive

Zalicus Granted Composition-of-Matter Patent For Synavive

Zalicus Inc. (NASDAQ: ZLCS) announced today that it has been granted a composition-of-matter patent by the U.

Zalicus Reports Financial Results For The Fourth Quarter And Year End 2010

Zalicus Reports Financial Results For The Fourth Quarter And Year End 2010

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the fourth quarter and year ended December 31, 2010.

Zalicus To Webcast Presentation And Conference Call Providing 2010 Financial Results And Company Update

Zalicus To Webcast Presentation And Conference Call Providing 2010 Financial Results And Company Update

Zalicus Inc. (NASDAQ: ZLCS) today announced that it will report financial results for the fourth quarter and year end 2010 before market opens on Wednesday, March 9, 2011 followed by a webcast presentation and ...

Zalicus Publishes Data On Sodium Channel Compound In Pain Models

Zalicus Publishes Data On Sodium Channel Compound In Pain Models

Zalicus Inc. (NASDAQ: ZLCS) today announced the publication of preclinical data in the journal PAIN.

Zalicus Announces Date Of Its 2011 Annual Meeting Of Stockholders

Zalicus Announces Date Of Its 2011 Annual Meeting Of Stockholders

Zalicus Inc. (NASDAQ: ZLCS) today announced that it currently plans to hold its 2011 Annual Meeting of Stockholders on May 24, 2011 at 8:30 a.

Zalicus To Present At The 13th Annual BIO CEO & Investor Conference

Zalicus To Present At The 13th Annual BIO CEO & Investor Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

6 Penny Stocks for the Biotech Boom

6 Penny Stocks for the Biotech Boom

Here are six small biotech companies with innovative technologies and cutting-edge treatments.

Zalicus To Present At The Biotech Showcase 2011 Conference

Zalicus To Present At The Biotech Showcase 2011 Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.

Zalicus To Present Data On Novel A2A Agonist Oncology Program At The American Society For Hematology Meeting

Zalicus To Present Data On Novel A2A Agonist Oncology Program At The American Society For Hematology Meeting

Zalicus Inc. (NASDAQ: ZLCS) announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the...

Zalicus To Present Data On Oncology Programs At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Meeting

Zalicus To Present Data On Oncology Programs At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Meeting

Zalicus Inc. (NASDAQ: ZLCS) presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting...

Zalicus Reports Financial Results For The Third Quarter 2010

Zalicus Reports Financial Results For The Third Quarter 2010

Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the third quarter ended September 30, 2010.

Zalicus To Present At The Wall Street Analyst Forum Analyst Conference

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Justin Renz, Senior Vice...

Zalicus Awarded $244,000 Therapeutic Discovery Project Grant

Zalicus Inc. (NASDAQ: ZLCS), innovators in the treatment of pain and immuno-inflammatory disease, today announced that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project (QTDP).

Zalicus Presents Data On Oncology Research At ASCO-NCI-EORTC Meeting

Zalicus Inc. (NASDAQ: ZLCS) presented data today on its research regarding novel synergistic drug combinations for the treatment of cancer at the ASCO-NCI-EORTC Molecular Markers meeting in Hollywood, FL on October 19,...

Zalicus To Present Corporate Updates In October

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Justin Renz, Senior Vice...

Zalicus Presents Data On Oncology Programs At Targeted Cancer Therapies World Europe 2010

Zalicus Inc. (NASDAQ: ZLCS) presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23,...

Zalicus To Present At The Fifth Annual JMP Securities Healthcare Conference

Zalicus To Present At The Fifth Annual JMP Securities Healthcare Conference

Zalicus, Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark Corrigan, President and...

Zalicus To Present At The Rodman & Renshaw Annual Global Investment Conference NYC

Press Kit Materials are Available at: http://www.tradeshownews.

Zalicus To Ring NASDAQ Closing Bell

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark Corrigan, President and...